Non-Alcoholic Steatohepatitis Treatment Market Segmentation:
Drug Type Segment Analysis
The vitamin E and pioglitazone segment in the non-alcoholic steatohepatitis treatment market is estimated to gain the largest revenue share by 2035. The growth of the segment is notably attributed to its worldwide use, backed by the effectiveness of its therapeutic kinetics. On this note, a study was published by the NLM in August 2023, demonstrating a significant reduction in steatosis, inflammation, ballooning, and liver markers in patients with NAFLD. The results were determined from a combination of randomized controll trials (RCTs), traditional reviews, systematic reviews, meta-analyses, and observational studies. The segment’s leadership is also testified by the worldwide trade of unmixed vitamin E derivatives, which accounted for USD 2.1 billion in 2023, with an annual growth rate of 3.8% in the past 5 years (OEC).
Distribution Channel Segment Analysis
The retail & specialty pharmacies segment is expected to garner a noteworthy revenue from the non-alcoholic steatohepatitis treatment market over the assessed timeline. The importance of a continuous course of drugs in treating NASH is securing a stable flow of business in this segment. In this regard, a 2024 NLM study concluded that the mean annual pharmaceutical spendings by each Medicare beneficiary were USD 4539, USD 6556 , and USD 6427, for non, compensated, and decompensated cirrhotic NASH candidates, respectively. The same was USD 9133, and USD 7348 for hepatocellular carcinoma and liver transplant. On the other hand, the connection between homecare facilities and retail pharmacies boosts the demand for off-label drugs, solidifying the segment’s significance in this sector.
Our in-depth analysis of the global non-alcoholic steatohepatitis treatment market includes the following segments:
|
Distribution Channel |
|
|
Drug Type |
|
